Numerous examples of the presence of LOXL2 in serum samples of fibrosis patients have pointed to LOXL2 as a potential biomarker for idiopathic pulmonary fibrosis [148], cardiac fibrosis [149], and other pathologies [150,151]. Here, LOXL2 is linked to fibrosis.